Overall, this phase 1b trial demonstrates that combined cagrilintide and semaglutide therapy is safe, well-tolerated, and offers clinically meaningful weight loss compared to placebo, warranting further investigation for weight management in obesity
2013;27:862.32) and meanwhile also published in PubMed, the leading international scientific database: Link to the publication | Link to the Infografic The study was conducted in collaboration with the Pennsylvania Department of Public Health Sciences, the Penn State Hershey Cancer Institute and the Penn State College of Medicine Hershey, PA/USA.
When stimulated simultaneously, the two receptors produce a synergistic GH pulse that substantially exceeds what either compound generates alone an effect documented in the broader GHRH + GHRP literature going back to the 1990s
Theranostics 13 , 49935016 (2023)
The single published case series showing symptomatic improvement following intra-articular BPC-157 injection for knee pain provides preliminary support for this indication, though the small sample size, retrospective design, and lack of imaging or biomarker assessment limit conclusions
Int J Mol Sci, 18 (3), doi: Chung, K
